EWTX

Rating neutralAI MemoPost-earnings T+3

Edgewise Therapeutics

As of 2026-05-09/Post-earnings T+3/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

CIRRUS-HCM 12-week Part D data due in Q2 2026 • 2026-06-30

Base target: $40 / p=45% prob

Biggest risk

This remains a high-dependency binary biotech story with no commercial revenue, higher year-over-year R&D spend, and value concentrated in upcoming clinical readouts. As of May 9, 2026, trusted post-earnings consensus surprise data and a clear T+3 analyst revision wave were not available in checked sources, which limits conviction that the earnings print itself changed the thesis materially.

Invalidation

Break below $24 or thesis failure.

What would change my mind?

The May 7, 2026 update kept the two most important clinical milestones intact: Q2 2026 CIRRUS-HCM data and Q4 2026 GRAND CANYON pivotal Becker data. The filing also showed $499.6 million of cash, cash equivalents and marketable securities at March 31, 2026, while the 10-Q says existing liquidity should fund planned operating expenses and capital expenditures for at least the next 12 months [#10-Q-2026-05-07].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-09

Base target

$40

p=45%

Bull target

$50

p=30%

Bear target

$24

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

HFpEF expansion could broaden the EDG-15400 story in 2H 2026
GRAND CANYON pivotal Becker readout remains the core value driver
The May 7, 2026 update kept the two most important clinical milestones intact: Q2 2026 CIRRUS-HCM data and Q4 2026 GRAND CANYON pivotal Becker data.

BearKey bullets

Clinical readouts in HCM or Becker could miss on efficacy, safety, or interpretability, which would pressure a pipeline-led valuation.
Late-stage execution risk remains high around GRAND CANYON enrollment, data quality, and eventual regulatory positioning for sevasemten.
Q1 2026 R&D expense rose to $42.7 million from $36.8 million year over year, and cash used in operating activities was $42.5 million in the quarter, so delays or added trial scope could pull financing needs forward despite at least 12 months of stated runway [#10-Q-2026-05-07].

WatchKey bullets

CIRRUS-HCM 12-week Part D data due in Q2 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Post-earnings T+3

Base case: $40 (p=45%)

Target spread vs base: +25% / -40%

Scenario probabilities

Bull Target: $50 (p=30%)Base Target: $40 (p=45%)Bear Target: $24 (p=25%)

Commentary

As of May 9, 2026, sentiment is cautiously constructive but not emphatic. Primary company materials were positive on long-term sevasemten data and reaffirmed Q2/Q4 milestones, yet the market reaction is muted: EWTX was $35.32 at the latest checked trade versus the May 7, 2026 anchor close of $35.58, about 0.7% lower. No trustworthy post-print analyst revision wave or clear consensus beat/miss dataset was confirmed in checked sources, so this still reads as a monitoring-style setup rather than a fully validated post-earnings rerating.

As of 2026-05-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

HFpEF expansion could broaden the EDG-15400 story in 2H 2026
GRAND CANYON pivotal Becker readout remains the core value driver

Scenarios

Bull Target (Scenario probability)

$50 / p=30% prob

Base Target (Scenario probability)

$40 / p=45% prob

Bear Target (Scenario probability)

$24 / p=25% prob

Analysis 2026-05-09 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-30
CIRRUS-HCM 12-week Part D data due in Q2 2026
Management said 12-week CIRRUS-HCM data for EDG-7500 in obstructive and nonobstructive HCM are expected in Q2 2026, making this the nearest high-impact readout from the May 7, 2026 earnings update [#8-K-2026-05-07].
Prob 75.00% • Move 18.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

HFpEF expansion could broaden the EDG-15400 story in 2H 2026
2026-09-30
Edgewise said it expects to initiate a Phase 2 HFpEF trial for EDG-15400 in the second half of 2026, which could expand the cardiovascular narrative beyond HCM if execution stays on track [#8-K-2026-05-07].
Prob 60% • Move 8% • Priced-in 25%
GRAND CANYON pivotal Becker readout remains the core value driver
2026-12-31
The company reiterated that pivotal GRAND CANYON top-line results for sevasemten in Becker muscular dystrophy are expected in Q4 2026; this remains the main thesis-changing catalyst and potential path toward a first marketing application [#8-K-2026-05-07].
Prob 65% • Move 35% • Priced-in 30%

Risks

Clinical readouts in HCM or Becker could miss on efficacy, safety, or interpretability, which would pressure a pipeline-led valuation.
Late-stage execution risk remains high around GRAND CANYON enrollment, data quality, and eventual regulatory positioning for sevasemten.
Q1 2026 R&D expense rose to $42.7 million from $36.8 million year over year, and cash used in operating activities was $42.5 million in the quarter, so delays or added trial scope could pull financing needs forward despite at least 12 months of stated runway [#10-Q-2026-05-07].
The earnings follow-up did not provide a strong verified analyst-revision signal as of May 9, 2026, leaving sentiment vulnerable to future estimate resets once sell-side models digest the print.

Peers

Symbol	Summary
ORKA	Oruka is a size-matched clinical-stage biotech, but it is not an indication-matched muscle-disease peer; useful mainly as a risk-capital and development-stage comparison.
TERN	Terns is another similar-cap clinical-stage biotech; it is a loose peer for pipeline-risk and cash-burn framing rather than a direct operating comp to Becker/HCM programs.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-09

Loading AI feed…

Symbol

Summary

ORKA

Oruka is a size-matched clinical-stage biotech, but it is not an indication-matched muscle-disease peer; useful mainly as a risk-capital and development-stage comparison.

TERN

Terns is another similar-cap clinical-stage biotech; it is a loose peer for pipeline-risk and cash-burn framing rather than a direct operating comp to Becker/HCM programs.